SHCBP1高表达促进鼻咽癌细胞上皮间质转化过程的分析
作者:
基金项目:

贵州省科学技术基金(黔科合基础-ZK[2021]一般424);贵州医科大学附属医院国家自然科学基金培育计划项目(gyfynsfc[2020]-7);贵州医科大学国家自然科学基金培育项目(20NSP023)。


High expression of SHCBP1 promotes epithelial-mesenchymal transition in nasopharyngeal carcinoma cells
Author:
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • | |
    摘要:

    目的 探究SHC SH2结构域结合蛋白1(SHCBP1)在鼻咽癌组织及鼻咽癌细胞系中的表达情况,分析其对鼻咽癌细胞系的增殖、侵袭能力及上皮间质转化(EMT)过程的影响。方法 利用TCGA数据库分析SHCBP1在头颈鳞状细胞癌(HNSC)中的表达情况,分析SHCBP1表达程度与肿瘤免疫细胞浸润程度的关系。同时收集2019年9月—2021年9月于贵州医科大学附属医院及贵州医科大学附属肿瘤医院经病理确诊的31例鼻咽癌初诊患者临床组织样本,所有患者就诊前均未接受任何放化疗,并收集同期就诊的31例疑似鼻咽癌但病检示慢性鼻咽炎组织作为对照组。利用逆转录实时荧光定量PCR(RT-qPCR)检测临床样本及鼻咽癌细胞系5-8F中SHCBP1的表达情况。细胞实验以鼻咽癌细胞系5-8F、正常鼻咽部永生化上皮细胞系NP69作为研究对象。采用利用慢病毒载体shRNA-SHCBP1干扰技术沉默5-8F细胞中SHCBP1表达,并分为NC组(空载慢病毒LV-Zs-Green-PURO-NC感染5-8F)、SHCBP1-shRNA组(LV-SHCBP1-shRNA-Zs-Green-PURO沉默5-8F细胞SHCBP1表达)。CCK-8法、克隆形成实验检测SHCBP1对鼻咽癌细胞增殖的影响;划痕实验、Transwell迁移、侵袭实验检测SHCBP1对鼻咽癌细胞的转移、侵袭能力的影响。Western blot检测NC组、SHCBP1-shRNA组中E-cadherin、N-cadherin、基质金属蛋白9(MMP9)、Vimentin的表达情况。结果 在HNSC中SHCBP1高表达,表达量与Th2细胞浸润程度相关。与慢性鼻咽炎组织相比,鼻咽癌组织中SHCBP1明显高表达,差异具有统计学意义(P<0.05)。与NC组相比,SHCBP1-shRNA组鼻咽癌细胞增殖、迁移、侵袭能力均减弱,差异具有统计学意义(P<0.05)。SHCBP1-shRNA组E-cadherin表达较NC组升高,N-cadherin、MMP9、Vimentin表达较NC组降低,差异具有统计学意义(P<0.05)。结论 SHCBP1在鼻咽癌中高表达,并可促进鼻咽癌细胞增殖、侵袭、迁移及激活EMT过程。

    Abstract:

    Objective To investigate the expression of Shc SH2-domain binding protein 1 (SHCBP1) gene in nasopharyngeal carcinoma (NPC) tissues and NPC cell lines, and its effect on the proliferation, invasion ability and epithelial-mesenchymal transition (EMT) process of NPC cell lines.Methods The expression of SHCBP1 in head and neck squamous cell carcinoma (HNSC) was analyzed by TCGA database, and the relationship between the expression of SHCBP1 and the degree of tumor immune cell infiltration was analyzed. The clinical tissue samples of 31 patients with NPC diagnosed by pathology in the Affiliated Hospital of Guizhou Medical University and the Affiliated Cancer Hospital of Guizhou Medical University from Sept 2019 to Sept 2021 were collected. At the same time, 31 cases of chronic nasopharyngitis were selected as the control group. The expression of SHCBP1 in clinical samples and NPC cell line 5-8F was detected by reverse transcriptase real-time fluorescence quantitative PCR (RT-qPCR). In the cell experiment, NPC cell line 5-8F and normal nasopharyngeal immortalized epithelial cell line NP69 were used as the subjects. SHCBP1 expression in 5-8F cells was silenced by lentiviral vector shRNA-SHCBP1 interference technique and divided into normal control (NC) group (empty viral vector infected with 5-8F) and SHCBP1-shRNA group (silencing SHCBP1 expression in 5-8F cells). The effect of SHCBP1 on the proliferation of NPC cells was detected by CCK-8 assay and clone formation assay, and the effect of SHCBP1 on the metastasis and invasion of NPC cells was detected by scratch test, Transwell migration and invasion test. Western blot was used to detect the expression of E-cadherin, N-cadherin, MMP9 and Vimentin in the NC group and SHCBP1-shRNA group.Results SHCBP1 was highly expressed in HNSC, and the expression was related to the degree of Th2 cell infiltration. Compared with the chronic nasopharyngitis, the expression of SHCBP1 in NPC was significantly elevated (P<0.05). The proliferation, migration and invasion of NPC cells in the SHCBP1-shRNA group were significantly lower than those in the NC group (P<0.05). The expression of E-cadherin in SHCBP1-shRNA group was higher than that in the NC group, while the expressions of N-cadherin, MMP9 and Vimentin were lower than those in the NC group.Conclusion SHCBP1 is highly expressed in NPC and can promote the proliferation, invasion, migration and activation of EMT in NPC cells.

    网友评论
    网友评论
    分享到微博
    发 布
    参考文献
    [1] Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma[J]. Lancet, 2019, 394(10192):64-80.
    [2] 朱振潮,邱前辉,詹建东,等.鼻咽癌组织中BLU与cyclin D1和cyclin B1的表达及其临床意义[J].中国耳鼻咽喉颅底外科杂志,2021,27(4):428-434.
    [3] Lebiedzinska-Arciszewska M, Oparka M, Vega-Naredo I, et al. The interplay between p66Shc, reactive oxygen species and cancer cell metabolism[J]. Eur J Clin Invest, 2015, 45 Suppl 1:25-31.
    [4] Zhang GY, Ma ZJ, Wang L, et al. The role of Shcbp1 in signaling and disease[J]. Curr Cancer Drug Targets, 2019, 19(11):854-862.
    [5] Georgakopoulos-Soares I, Chartoumpekis DV, Kyriazopoulou V, et al. EMT factors and metabolic pathways in cancer[J]. Front Oncol, 2020, 10:499.
    [6] Sun Y, Pan H, He Y, et al. Functional roles of the SHCBP1 and KIF23 interaction in modulating the cell-cycle and cisplatin resistance of head and neck squamous cell carcinoma[J]. Head Neck, 2022, 44(3):591-605.
    [7] Yin H, Zhang C, Wei Z, et al. EGF-induced nuclear translocation of SHCBP1 promotes bladder cancer progression through inhibiting RACGAP1-mediated RAC1 inactivation[J]. Cell Death Dis, 2022, 13(1):39.
    [8] Romeo E, Caserta CA, Rumio C, et al. The vicious cross-talk between tumor cells with an EMT phenotype and cells of the immune system[J]. Cells, 2019, 8(5):460.
    [9] Peng C, Zhao H, Song Y, et al. SHCBP1 promotes synovial sarcoma cell metastasis via targeting TGF-beta1/Smad signaling pathway and is associated with poor prognosis[J]. J Exp Clin Cancer Res, 2017, 36(1):141.
    [10] Liu L, Yang Y, Liu S, et al. EGF-induced nuclear localization of SHCBP1 activates beta-catenin signaling and promotes cancer progression[J]. Oncogene, 2019, 38(5):747-764.
    [11] Lu Y, Zhou X, Zhao W, et al. Epigenetic inactivation of Acetyl-CoA Acetyltransferase 1 promotes the proliferation and metastasis in nasopharyngeal carcinoma by blocking ketogenesis[J]. Front Oncol, 2021, 11:667673.
    [12] Wu A, Luo N, Xu Y, et al. Exosomal LBH inhibits epithelial-mesenchymal transition and angiogenesis in nasopharyngeal carcinoma via downregulating VEGFA signaling[J]. Int J Biol Sci, 2022, 18(1):242-260.
    [13] Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer[J]. Immunity, 2013, 39(4):782-795.
    [14] 邱烨,张俊杰.鼻咽癌早期筛查的研究进展[J],中国耳鼻咽喉颅底外科杂志,2020,26(2):201-204.
    [15] Huang T, Ploner A, Chang ET, et al. Dietary patterns and risk of nasopharyngeal carcinoma:a population-based case-control study in southern China[J]. Am J Clin Nutr, 2021, 114(2):462-471.
    [16] 中国医师协会放射肿瘤治疗医师分会,中华医学会放射肿瘤治疗学分会.中国鼻咽癌放射治疗指南(2020版)[J].中华肿瘤防治杂志, 2021, 28(3):167-177.
    [17] Liu Z, Chen Y, Su Y, et al. Nasopharyngeal carcinoma:Clinical achievements and considerations among treatment options[J]. Front Oncol, 2021, 11:635737.
    [18] Yang C, Hu JF, Zhan Q, et al. SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer[J]. Genomics, 2021, 113(2):827-842.
    [19] Zou A, Wu A, Luo M, et al. SHCBP1 promotes cisplatin induced apoptosis resistance, migration and invasion through activating Wnt pathway[J]. Life Sci, 2019, 235:116798.
    [20] Xu N, Wu YP, Yin HB, et al. SHCBP1 promotes tumor cell proliferation, migration, and invasion, and is associated with poor prostate cancer prognosis[J]. J Cancer Res Clin Oncol, 2020, 146(8):1953-1969.
    [21] Zhou Y, Tan Z, Chen K, et al. Overexpression of SHCBP1 promotes migration and invasion in gliomas by activating the NF-kappaB signaling pathway[J]. Mol Carcinog, 2018, 57(9):1181-1190.
    [22] Feng W, Li HC, Xu K, et al. SHCBP1 is over-expressed in breast cancer and is important in the proliferation and apoptosis of the human malignant breast cancer cell line[J]. Gene, 2016, 587(1):91-97.
    [23] Nieto MA, Huang RY, Jackson RA, et al. Emt:2016[J]. Cell, 2016, 166(1):21-45.
    [24] Zhu Y, Tao Z, Chen Y, et al. Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT[J]. Breast Cancer Res Treat, 2022,193(1):65-81.
    [25] Buckley MW, Arandjelovic S, Trampont PC, et al. Unexpected phenotype of mice lacking Shcbp1, a protein induced during T cell proliferation[J]. PLoS One, 2014, 9(8):e105576.
    引证文献
引用本文

鲜志芃,喻国冻,张田,吴志敏,周方伟. SHCBP1高表达促进鼻咽癌细胞上皮间质转化过程的分析[J].中国耳鼻咽喉颅底外科杂志,2023,29(2):65-72

复制
分享
文章指标
  • 点击次数:67
  • 下载次数: 205
历史
  • 收稿日期:2022-03-18
  • 在线发布日期: 2023-05-05
温馨提示

本刊唯一投稿网址:www.xyosbs.com
唯一办公邮箱:xyent@126.com
编辑部联系电话:0731-84327210,84327469
本刊从未委托任何单位、个人及其他网站代理征稿及办理其他业务联系,谨防上当受骗!

关闭